Using ascites at two consecutive time points from two cancer patients with supposedly different aggressiveness (Pt 1 mixed ovarian cancer G1, Pt 2 serous peritoneal cancer G3), these experiments showed a reduction of SFRP4 protein expression during progressive chemoresistant disease (Figure 1 C, D). The gene discussed is SFRP4; the disease is ovarian cancer.